Pryce Introduces Bill To Reimbuse For Orally Administered Cancer Drugs.
H. Lee Moffitt Cancer Designated A Comprehensive Cancer Center By NCI.
DeMets Receives Lectureship On Epidemiology From NIH.
Generic Paclitaxel Approval Withstands Court Challenge.
Obit: J. Gale Katterhagen, NCAB’s First Community Physician.
NCI Invites “Extraordinary Opportunities” For Research. Groups Planning Promotion Of Cancer Clinical Trials.
FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.
M. D. Anderson Buys Record System For In-Patient Services From Atlanta Firm.
Genetronics Phase II Trials For Head & Neck Completed.
Biomira Ends Agreement On Lymphoma Vaccine.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- As more people are surviving cancer, we must continue funding bold science
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis
